A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Behçet Disease

Inclusion Criteria: * Diagnosis of Behçet Disease. At the time of diagnosis, subjects must meet the international study group criteria for Behçet Disease * Females of childbearing potential (FCBP) must have negative pregnancy tests and agree to use two forms of contraception throughout the study. * Males must use barrier contraception (latex condoms) when engaging in reproductive sexual activity with FCBP * Laboratory criteria: Hgb ≥ 9 g/dL, WBC count ≥ 3000 /microL and ≤14,000/microL, platelet count ≥ 100,000 /microL,, serum creatinine ≤ 1.5 mg/dL (≤ 132.6 μmol/L), total bilirubin ≤ 2.0 mg/dL, AST and ALT ≤ 1.5 X ULN * Two or more oral ulcers over the 28 day period before screening, with or without current treatment * Two or more oral ulcers at the time of randomization (Visit 2, Baseline) Exclusion Criteria: * Pregnant or breast feeding * Any condition which places the subject at risk * Systemic fungal infection * History of TB infection within 3 years * History of recurrent bacterial infection * Mycobacterium TB as indicated by a positive PPD skin test * History of incompletely treated Mycobacterium tuberculosis * Clinically significant chest x-ray abnormality at screening. * Clinically significant ECG abnormality at screening * History of HIV infection * History of congenital or acquired immunodeficiency * Hepatitis B surface antigen positive or Hepatitis B core antibody positive at screening * Antibodies to Hepatitis C at screening * History of malignancy (except for …